01 / ATLAS

What it is

KPV is the lysine–proline–valine sequence, a tripeptide investigated for its effects on inflammatory signaling. [1]

02 / ATLAS

How it works

In experimental models, the PepT1 transporter enabled KPV to enter cells. Researchers observed reductions in some inflammatory signaling pathways and cytokine secretion. [1]

03 / ATLAS

What research shows

Cell and mouse studies provide a basis for further investigation. They do not demonstrate an effective treatment for ulcerative colitis or Crohn’s disease in people. [1]

04 / ATLAS

Study data

Dalmasso et al., 2008: cell cultures and mouse colitis models, evaluating PepT1 transport and inflammation. Experimental animal doses are not converted into recommendations for humans here. [1]

05 / ATLAS

Safety and observed adverse reactions

The FDA reports a lack of identified human exposure data for KPV and insufficient information to assess safety. [2]

06 / ATLAS

Research status

The evidence presented is preclinical. Clinical efficacy, dose and safety for the discussed indications are not established by the cited study.

07 / REFERENCES

Studies and sources

  1. Dalmasso et al. · PepT1 and KPV (2008) ↗Original research · cells and animal models
  2. FDA · Safety information for KPV ↗Official assessment · United States
Back to the atlasFurther information / Contact